TOKYO -- Drugmakers from Japan, the U.S. and Europe have announced a more than $1 billion fund to invest in startups developing treatments for antibiotic-resistant infections.
The 23 companies include Eisai, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical and Chugai Pharmaceutical from Japan, as well as Amgen and Eli Lilly from the U.S. and Novartis and GlaxoSmithKline from Europe. The World Health Organization and the European Investment Bank also form part of the effort.
